PDCD1LG2 and cancer: In cancer, loss of function mutations in JAK2 are relatively often observed and can in principle result in decreased antigen presentation, lack of T cell infiltrates, tumor cell resistance to the anti-proliferative effects of IFN-γ, and can prevent adaptive PD-L1 and PD-L2 expression upon IFN-γ exposure [41, 42].